SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000925421-20-000248
Filing Date
2020-06-12
Accepted
2020-06-12 18:33:27
Documents
1
Period of Report
2020-06-10

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT edgar.html 4  
1 PRIMARY DOCUMENT edgar.xml 4 9307
  Complete submission text file 0000925421-20-000248.txt   11479
Mailing Address LICHTSTRASSE 35 BASEL V8 CH 4056
Business Address LICHTSTRASSE 35 BASEL V8 CH 4056 01141613241111
NOVARTIS AG (Reporting) CIK: 0001114448 (see all company filings)

State of Incorp.: V8 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-39114 | Film No.: 20961484
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000
Business Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000 41-61-324-6210
Novartis Bioventures Ltd (Reporting) CIK: 0001297709 (see all company filings)

State of Incorp.: D0 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-39114 | Film No.: 20961483

Mailing Address 2 WEST LIBERTY BLVD #100 MALVERN PA 19355
Business Address 2 WEST LIBERTY BLVD #100 MALVERN PA 19355 610-725-1500
Galera Therapeutics, Inc. (Issuer) CIK: 0001563577 (see all company filings)

IRS No.: 461454898 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations